Loading
companiesCompany
AP Biosciences
AP Biosciences is a Taiwan-based biotechnology company running 2 late-stage cancer trials of AP203, AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion) in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer.
Also called: AP Biosciences Inc.
Overview
AP Biosciences, based in Taipei, Taiwan, is a biotechnology company listed as TPEx: 6945. AP Biosciences develops biopharmaceuticals through mechanism-based drug design, focusing on tumour-associated antigens and disease-specific targets. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing AP203, AP402 (Part 1 Dose esclation) and AP402 (Part 2 Dose Expansion) in non-small-cell lung cancer, head and neck squamous cell carcinoma and oesophageal cancer. The largest, NCT05473156 (A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumours, and Expansion to Selected Malignancies), plans to enrol 168 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.